AP Biosciences (ROCO:6945) Ending Cash Position: NT$294.52 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:6945 AP Biosciences Inc ROCO:6945
21 GF Score
Price NT$95.30
! 1 Warning Sign
View Full Analysis

What is AP Biosciences Ending Cash Position?

AP Biosciences ROCO:6945 -0.31% 21 Ending Cash Position is NT$294.52 Mil as of Jun. 2026. GuruFocus rates ROCO:6945 with a GF Score™ of 21/100. The stock has 1 warning sign investors should review.

AP Biosciences's Ending Cash Position for the quarter that ended in Jun. 2026 was NT$294.52 Mil.

AP Biosciences's quarterly Ending Cash Position declined from Dec. 2025 (NT$970.89 Mil) to Mar. 2026 (NT$896.91 Mil) and declined from Mar. 2026 (NT$896.91 Mil) to Jun. 2026 (NT$294.52 Mil).

AP Biosciences's annual Ending Cash Position increased from Dec. 2023 (NT$278.61 Mil) to Dec. 2024 (NT$1,441.64 Mil) but then declined from Dec. 2024 (NT$1,441.64 Mil) to Dec. 2025 (NT$970.89 Mil).

AP Biosciences Ending Cash Position Related Terms

AP Biosciences Ending Cash Position Historical Data

* Premium members only.

The historical data trend for AP Biosciences's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

AP Biosciences Ending Cash Position Chart

AP Biosciences Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Ending Cash Position
Get a 7-Day Free Trial 527.12 1,048.00 278.61 1,441.64 970.89

AP Biosciences Quarterly Data
Dec20 Dec21 Dec22 Jun23 Dec23 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1,361.17 1,074.19 970.89 896.91 294.52
ROCO:6945
21GF Score
AP Biosciences Inc ROCO:6945
Ending Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

AP Biosciences Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

AP Biosciences's Ending Cash Position for the fiscal year that ended in Dec. 2025 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=1441.642+-470.75
=970.89

AP Biosciences's Ending Cash Position for the quarter that ended in Jun. 2026 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=896.912+-602.396
=294.52

Frequently Asked Questions Learn more about Ending Cash Position →
What does a Ending Cash Position of NT$294.52 Mil mean?
AP Biosciences (ROCO:6945) has a Ending Cash Position of NT$294.52 Mil as of Jun. 2026. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on AP Biosciences and its competitors.
Is AP Biosciences' Ending Cash Position too high?
AP Biosciences' current Ending Cash Position is NT$294.52 Mil. Overall, AP Biosciences has a GF Score™ of 21/100, reflecting its overall financial health beyond just this single metric.
How does AP Biosciences' Ending Cash Position compare to VRTX and REGN?
AP Biosciences' Ending Cash Position of NT$294.52 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Ending Cash Position for a Biotechnology company?
A good Ending Cash Position depends on the Biotechnology industry context. However, Ending Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Ending Cash Position mean?
A high Ending Cash Position can signal that a stock is expensive relative to its fundamentals. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on AP Biosciences and its competitors. AP Biosciences's current Ending Cash Position is NT$294.52 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AP Biosciences stock overvalued right now?
AP Biosciences (ROCO:6945) has a current Ending Cash Position of NT$294.52 Mil. The current Ending Cash Position is NT$294.52 Mil. AP Biosciences' overall GF Score™ is 21/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Ending Cash Position calculated?
Ending Cash Position is calculated from a company's financial statements. For AP Biosciences (ROCO:6945), the current Ending Cash Position is NT$294.52 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

AP Biosciences Business Description

Address No. 3, Park Street, 17th Floor, Taipei, TWN
AP Biosciences Inc is a clinical-stage bispecific antibody new drug research and development company. It has developed a series of antibody and protein lead drugs through a self-designed technology platform for unmet medical needs, focusing on Specific targets associated with diseases to deliver safe, effective and cost-effective medicines.
21GF Score

Get the complete analysis for ROCO:6945

Ending Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$95.30
Price